Hyperfine, Inc. (NASDAQ:HYPR) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analysts have a consensus recommendation of Hold on Hyperfine (1 sell, 2 hold, 2 buy) with an average 12‑month price target of $1.45.
• In the most recent quarter Hyperfine reported a loss per share of $0.06 (beating estimates by $0.02) with revenue of $5.29M roughly in line, but the company remains unprofitable (negative ROE and net margin) and is forecast to post a fiscal‑year EPS of -0.57; the stock trades around $1.24 with a market cap of $120.49M and a 12‑month range of $0.53–$2.22.
• Hyperfine’s flagship product, the Swoop portable MRI, targets bedside neuroimaging in emergency departments, ICUs and outpatient clinics to reduce logistical and financial barriers to MRI access.

Hyperfine, Inc. (NASDAQ:HYPR - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $1.45.

A number of brokerages have commented on HYPR. Lake Street Capital lifted their price target on Hyperfine from $2.00 to $2.50 and gave the stock a "buy" rating in a research note on Thursday. Zacks Research raised Hyperfine to a "hold" rating in a research note on Thursday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Hyperfine in a report on Thursday, January 22nd.

Hyperfine Stock Up 2.5%

NASDAQ HYPR opened at $1.24 on Friday. The company has a 50-day simple moving average of $1.15 and a two-hundred day simple moving average of $1.20. Hyperfine has a 12-month low of $0.53 and a 12-month high of $2.22. The firm has a market cap of $120.49 million, a price-to-earnings ratio of -2.82 and a beta of 1.09.

Hyperfine (NASDAQ:HYPR - Get Free Report) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $5.29 million for the quarter, compared to the consensus estimate of $5.30 million. Hyperfine had a negative return on equity of 95.09% and a negative net margin of 262.29%. Equities analysts expect that Hyperfine will post -0.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hyperfine

Several hedge funds and other institutional investors have recently modified their holdings of HYPR. Catalio Capital Management LP boosted its holdings in shares of Hyperfine by 92.8% during the fourth quarter. Catalio Capital Management LP now owns 1,320,041 shares of the company's stock worth $1,293,000 after purchasing an additional 635,500 shares during the period. Renaissance Technologies LLC increased its holdings in Hyperfine by 674.4% during the 4th quarter. Renaissance Technologies LLC now owns 364,743 shares of the company's stock valued at $357,000 after purchasing an additional 317,645 shares during the period. Walleye Capital LLC bought a new position in Hyperfine during the 4th quarter valued at approximately $212,000. Vanguard Group Inc. raised its position in Hyperfine by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company's stock valued at $5,092,000 after purchasing an additional 190,136 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Hyperfine by 21.4% in the 4th quarter. Geode Capital Management LLC now owns 815,986 shares of the company's stock worth $799,000 after buying an additional 143,975 shares during the period. 15.03% of the stock is owned by institutional investors.

Hyperfine Company Profile

Hyperfine, Inc NASDAQ: HYPR is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company's flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient's bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.